Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Head and Neck Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 68 articles:
HTML format
Text format



Single Articles


    April 2019
  1. PENG H, Dong D, Fang M, Li L, et al
    Prognostic Value of Deep Learning PET/CT-based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2019 Apr 11. pii: 1078-0432.CCR-18-3065.
    PubMed     Text format     Abstract available


  2. WON E, Basunia A, Chatila WK, Hechtman JF, et al
    Efficacy of combined VEGFR1-3, PDGFalpha/beta, and FGFR1-3 blockade using nintedanib for esophagogastric cancer.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-18-3789.
    PubMed     Text format     Abstract available


    February 2019
  3. MIYAUCHI S, Kim SS, Pang J, Gold KA, et al
    Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics.
    Clin Cancer Res. 2019 Feb 27. pii: 1078-0432.CCR-18-0871.
    PubMed     Text format     Abstract available


  4. LEE JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, et al
    Combined Aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2019 Feb 12. pii: 1078-0432.CCR-18-0440.
    PubMed     Text format     Abstract available


  5. SALEH A, Cheng H, Martin SE, Si H, et al
    Integrated genomic and functional microRNA analysis identifies miR-30-5p as a tumor suppressor and potential therapeutic nanomedicine in head and neck cancer.
    Clin Cancer Res. 2019 Feb 5. pii: 1078-0432.CCR-18-0716.
    PubMed     Text format     Abstract available


    January 2019
  6. DIGOMANN D, Kurth I, Tyutyunnykova A, Chen O, et al
    The CD98 heavy chain is a marker and regulator of head and neck squamous cell carcinoma radiosensitivity.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2951.
    PubMed     Text format     Abstract available


    December 2018
  7. HUANG L, David O, Cabay RJ, Valyi-Nagy K, et al
    Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer.
    Clin Cancer Res. 2018 Dec 20. pii: 1078-0432.CCR-18-1884.
    PubMed     Text format     Abstract available


  8. LI F, Xu Y, Liu B, Singh PK, et al
    YAP1-mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the combination of YAP1 and CDK4/6 inhibitors in Esophageal Cancer.
    Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-1029.
    PubMed     Text format     Abstract available


  9. CALIFANO JA, Khan Z, Noonan KA, Rudraraju L, et al
    Correction: Tadalafil Augments Tumor-specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2018;24:6100.
    PubMed     Text format    


  10. BRAND TM, Iida M, Stein AP, Corrigan KL, et al
    Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2018;24:6099.
    PubMed     Text format    


    November 2018
  11. ZHANG H, Hua Y, Jiang Z, Yue J, et al
    Cancer associated fibroblasts-promoted LncRNA DNM3OS confers radioresistance by regulating DNA damage response in esophageal squamous cell carcinoma.
    Clin Cancer Res. 2018 Nov 21. pii: 1078-0432.CCR-18-0773.
    PubMed     Text format     Abstract available


  12. DAY TA, Shirai K, O'Brien PE, Matheus MG, et al
    Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
    Clin Cancer Res. 2018 Nov 12. pii: 1078-0432.CCR-18-2024.
    PubMed     Text format     Abstract available


  13. CLUMP DA, Pickering CR, Skinner HD
    Predicting Outcome in Head and Neck Cancer: miRNAs with potentially big effects.
    Clin Cancer Res. 2018 Nov 9. pii: 1078-0432.CCR-18-3078.
    PubMed     Text format     Abstract available


    October 2018
  14. DILLON MT, Grove L, Newbold KL, Shaw H, et al
    Patritumab with Cetuximab Plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase-Ib Study.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-1539.
    PubMed     Text format     Abstract available


    September 2018
  15. AGGARWAL C, Cohen RB, Morrow MP, Kraynak KA, et al
    Immunotherapy targeting HPV 16/18 generates potent immune responses in HPV-Associated Head and Neck Cancer.
    Clin Cancer Res. 2018 Sep 21. pii: 1078-0432.CCR-18-1763.
    PubMed     Text format     Abstract available


  16. LUO J, Bian L, Blevins MA, Wang D, et al
    Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model.
    Clin Cancer Res. 2018 Sep 5. pii: 1078-0432.CCR-18-1081.
    PubMed     Text format     Abstract available


    August 2018
  17. HESS J, Unger K, Maihoefer C, Schuttrumpf L, et al
    A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV-infection.
    Clin Cancer Res. 2018 Aug 31. pii: 1078-0432.CCR-18-0776.
    PubMed     Text format     Abstract available


  18. LI YQ, Yang XJ, Du XJ, Lei Y, et al
    RAB37 hypermethylation regulates metastasis and resistance to docetaxel-based induction chemotherapy in nasopharyngeal carcinoma.
    Clin Cancer Res. 2018 Aug 21. pii: 1078-0432.CCR-18-0532.
    PubMed     Text format     Abstract available


  19. LIU Q, Ma L, Jones T, Palomero L, et al
    Subjugation of TGFbeta Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End-Joining.
    Clin Cancer Res. 2018 Aug 7. pii: 1078-0432.CCR-18-1346.
    PubMed     Text format     Abstract available


  20. PRETE A, Lo AS, Sadow PM, Bhasin SS, et al
    Pericytes elicit resistance to vemurafenib and sorafenib therapy in thyroid carcinoma via the TSP-1/TGFbeta1 axis.
    Clin Cancer Res. 2018 Aug 3. pii: 1078-0432.CCR-18-0693.
    PubMed     Text format     Abstract available



  21. Correction: A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Clin Cancer Res. 2018;24:3781.
    PubMed     Text format    


    July 2018
  22. KARAM SD, Reddy K, Blatchford P, Waxweiler T, et al
    Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0467.
    PubMed     Text format     Abstract available


    June 2018
  23. LIU C, Guo T, Xu G, Sakai A, et al
    Characterization of alternative splicing events in HPV negative head and neck squamous cell carcinoma identifies an oncogenic DOCK5 variant.
    Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-18-0752.
    PubMed     Text format     Abstract available


    May 2018
  24. BHATIA S, Sharma J, Bukkapatnam S, Oweida A, et al
    Inhibition of EphB4-ephrin-B2 signaling enhances response to Cetuximab-radiation therapy in head and neck cancers.
    Clin Cancer Res. 2018 May 30. pii: 1078-0432.CCR-18-0327.
    PubMed     Text format     Abstract available


  25. TAN YS, Sansanaphongpricha K, Xie Y, Donnelly CR, et al
    Mitigating SOX2-potentiated immune escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing nanosatellite vaccine.
    Clin Cancer Res. 2018 May 16. pii: 1078-0432.CCR-17-2807.
    PubMed     Text format     Abstract available


    April 2018
  26. LIU Z, McMichael EL, Shayan G, Li J, et al
    Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients.
    Clin Cancer Res. 2018 Apr 30. pii: 1078-0432.CCR-17-1350.
    PubMed     Text format     Abstract available


    March 2018
  27. XU C, Nikolova O, Basom R, Mitchell RM, et al
    Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1339.
    PubMed     Text format     Abstract available


  28. MENDEZ E, Rodriguez CP, Kao M, Raju SC, et al
    A Phase I Clinical Trial of AZD1775 in Combination With Neoadjuvant Weekly Docetaxel and Cisplatin Before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-3796.
    PubMed     Text format     Abstract available


  29. ZHAO X, Brusadelli MG, Sauter SL, Butsch Kovacic M, et al
    Lipidomic profiling links the Fanconi anemia pathway to glycosphingolipid metabolism in head and neck cancer cells.
    Clin Cancer Res. 2018 Mar 12. pii: 1078-0432.CCR-17-3686.
    PubMed     Text format     Abstract available


    February 2018
  30. SOULIERES D, Lictira L, Mesia R, Remenar E, et al
    Molecular Alterations and Buparlisib Efficacy in Patients With Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis From BERIL-1.
    Clin Cancer Res. 2018 Feb 28. pii: 1078-0432.CCR-17-2644.
    PubMed     Text format     Abstract available


  31. CHEN YP, Tang LL, Yang Q, Poh SS, et al
    Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials.
    Clin Cancer Res. 2018 Feb 5. pii: 1078-0432.CCR-17-2656.
    PubMed     Text format     Abstract available


  32. LABAN S, Hoffmann TK
    Human Papillomavirus Immunity in Oropharyngeal Cancer: Time to Change the Game?
    Clin Cancer Res. 2018;24:505-507.
    PubMed     Text format     Abstract available


    January 2018
  33. HUI EP, Ma BBY, Loong H, Mo F, et al
    Efficacy, safety and pharmacokinetics of axitinib in nasopharyngeal carcinoma: a preclinical and phase 2 correlative study.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-1667.
    PubMed     Text format     Abstract available


  34. COGHILL AE, Pfeiffer RM, Proietti C, Hsu WL, et al
    Identification of a novel, EBV-based antibody risk stratification signature for early detection of nasopharyngeal carcinoma in Taiwan.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-1929.
    PubMed     Text format     Abstract available


  35. SCHMIDT S, Linge A, Zwanenburg A, Leger S, et al
    Development and validation of a gene signature for patients with head and neck squamous cell carcinomas treated by postoperative radio(chemo)therapy.
    Clin Cancer Res. 2018 Jan 3. pii: 1078-0432.CCR-17-2345.
    PubMed     Text format     Abstract available


    December 2017
  36. THEODORAKI MN, Yerneni S, Hoffmann TK, Gooding WE, et al
    Clinical significance of PD-L1+ exosomes in plasma of Head and Neck Cancer patients.
    Clin Cancer Res. 2017 Dec 12. pii: 1078-0432.CCR-17-2664.
    PubMed     Text format     Abstract available


  37. CHUNG MK, Jung YH, Lee JK, Cho SY, et al
    CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma Through the Upregulation of Slug.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-0866.
    PubMed     Text format     Abstract available


    November 2017
  38. KRAFT IL, Akshintala S, Zhu YJ, Lei H, et al
    Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
    Clin Cancer Res. 2017 Nov 29. pii: 1078-0432.CCR-17-2101.
    PubMed     Text format     Abstract available


  39. WANG X, Beitler JJ, Huang W, Chen G, et al
    Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-0345.
    PubMed     Text format     Abstract available


  40. FUKUSUMI T, Guo T, Sakai A, Ando M, et al
    The NOTCH4-HEY1 pathway induces epithelial mesenchymal transition in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2017 Nov 16. pii: clincanres.1366.2017.
    PubMed     Text format     Abstract available


  41. ZHONG Q, Liu Z, Lin ZR, Hu ZD, et al
    The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2017 Nov 13. pii: clincanres.0352.2016.
    PubMed     Text format     Abstract available


  42. LIU X, Kumar M, Yang L, Molkentine DP, et al
    BAP1 is a novel target in HPV negative head and neck cancer.
    Clin Cancer Res. 2017 Nov 7. pii: clincanres.1573.2017.
    PubMed     Text format     Abstract available


  43. LIN C, Zhang N, Wang Y, Wang Y, et al
    Functional Role of A Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis.
    Clin Cancer Res. 2017 Nov 3. pii: clincanres.1851.2017.
    PubMed     Text format     Abstract available


    October 2017
  44. SHAYAN G, Kansy BA, Gibson SP, Srivastava RM, et al
    A Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.0357.2017.
    PubMed     Text format     Abstract available


  45. NIEHR F, Eder T, Pilz T, Konschak R, et al
    Multilayered omics-based analysis of a head and neck cancer model of cisplatin resistance reveals intratumoral heterogeneity and treatment-induced clonal selection.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.2410.2017.
    PubMed     Text format     Abstract available


  46. YANG Q, Zhang MX, Zou X, Liu YP, et al
    A prognostic bio-model based on SQSTM1 and N stage identifies nasopharyngeal carcinoma patients at high risk of metastasis for additional induction chemotherapy.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1963.2017.
    PubMed     Text format     Abstract available


  47. MIN IM, Shevlin E, Vedvyas Y, Zaman M, et al
    CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors.
    Clin Cancer Res. 2017 Oct 12. pii: clincanres.2008.2017.
    PubMed     Text format     Abstract available


    September 2017
  48. WOOD O, Clarke J, Woo J, Mirza AH, et al
    Head and neck squamous cell carcinomas are characterized by a stable immune signature within the primary tumor over time.
    Clin Cancer Res. 2017 Sep 26. pii: clincanres.0373.2017.
    PubMed     Text format     Abstract available


  49. BIKTASOVA AK, Hajek M, Sewell AB, Gary CS, et al
    Demethylation therapy as a targeted treatment for human papilloma virus-associated head and neck cancer.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1438.2017.
    PubMed     Text format     Abstract available


    July 2017
  50. WHITESIDE TL
    Head and Neck Carcinoma Immunotherapy: Facts and Hopes.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1261.2017.
    PubMed     Text format     Abstract available


  51. MELL LK, Brumund KT, Daniels GA, Advani SJ, et al
    PHASE I TRIAL OF INTRAVENOUS ONCOLYTIC VACCINIA VIRUS (GL-ONC1) WITH CISPLATIN AND RADIOTHERAPY IN PATIENTS WITH LOCOREGIONALLY ADVANCED HEAD AND NECK CARCINOMA.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.3232.2016.
    PubMed     Text format     Abstract available


    June 2017
  52. IBRAHIMPASIC T, Xu B, Landa I, Dogan S, et al
    Genomic alterations in fatal forms of non-anaplastic thyroid cancer: Identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence.
    Clin Cancer Res. 2017 Jun 20. pii: clincanres.1183.2017.
    PubMed     Text format     Abstract available


  53. LU G, Little JV, Wang X, Zhang H, et al
    Detection of Head and Neck Cancer in Surgical Specimens Using Quantitative Hyperspectral Imaging.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.0906.2017.
    PubMed     Text format     Abstract available


  54. KOTIAN S, Zhang L, Boufraqech M, Gaskins K, et al
    Dual Inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.1043.2017.
    PubMed     Text format     Abstract available


    May 2017
  55. OZAWA H, Ranaweera R, Izumchenko E, Makarev E, et al
    SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cells.
    Clin Cancer Res. 2017 May 18. pii: clincanres.1686.2016.
    PubMed     Text format     Abstract available


  56. CHOW LQM, Morishima C, Eaton KD, Baik CS, et al
    Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
    Clin Cancer Res. 2017;23:2442-2450.
    PubMed     Text format     Abstract available


  57. SKINNER HD, Giri U, Yang LP, Kumar M, et al
    Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
    Clin Cancer Res. 2017 May 5. doi: 10.1158/1078-0432.CCR-16-2586.
    PubMed     Text format     Abstract available


  58. TZENG HT, Tsai CH, Yen YT, Cheng HC, et al
    Dysregulation of Rab37-Mediated Cross-talk between Cancer Cells and Endothelial Cells via Thrombospondin-1 Promotes Tumor Neovasculature and Metastasis.
    Clin Cancer Res. 2017;23:2335-2345.
    PubMed     Text format     Abstract available


  59. UPPALURI R, Winkler AE, Lin T, Law JH, et al
    Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.
    Clin Cancer Res. 2017;23:2186-2194.
    PubMed     Text format     Abstract available


    April 2017
  60. ROSENTHAL E, Moore L, Tipirneni K, de Boer E, et al
    Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.2968.2016.
    PubMed     Text format     Abstract available


  61. SALOURA V, Fatima A, Zewde M, Kiyotani K, et al
    Characterization of the tumor T-cell receptor repertoire and immune microenvironment in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2017 Apr 25. pii: clincanres.0103.2017.
    PubMed     Text format     Abstract available


  62. LUDWIG S, Floros T, Theodoraki MN, Hong CS, et al
    Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.2819.2016.
    PubMed     Text format     Abstract available


    March 2017
  63. DERAKHSHAN A, Chen Z, Van Waes C
    Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways.
    Clin Cancer Res. 2017;23:1379-1387.
    PubMed     Text format     Abstract available


    January 2017
  64. KANG H, Tan M, Bishop JA, Jones S, et al
    Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma.
    Clin Cancer Res. 2017;23:283-288.
    PubMed     Text format     Abstract available


    October 2016
  65. RAUE F, Frank-Raue K
    Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
    Clin Cancer Res. 2016;22:5012-5021.
    PubMed     Text format     Abstract available


    July 2016
  66. ZHU X, Enomoto K, Zhao L, Zhu YJ, et al
    Bromodomain and extraterminal protein inhibitor JQ1 suppresses thyroid tumor growth in a mouse model.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.0914.2016.
    PubMed     Text format     Abstract available


    June 2016
  67. ABDULGHANI J, Gokare P, Gallant JN, Dicker DT, et al
    Sorafenib and quinacrine target anti-apoptotic protein Mcl-1: a poor prognostic marker in anaplastic thyroid cancer (ATC).
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.2792.2015.
    PubMed     Text format     Abstract available


    February 2016
  68. YU XM, Jaskula-Sztul R, Georgen MR, Aburjania Z, et al
    Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression.
    Clin Cancer Res. 2016 Feb 4. pii: clincanres.1749.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: